Janux Therapeutics Inc (JANX)

$42

-0.37

(-0.87%)

Market is closed - opens 7 PM, 17 Jun 2024

Insights on Janux Therapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 2.51M → 1.25M (in $), with an average decrease of 25.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -11.56M → -14.76M (in $), with an average decrease of 13.6% per quarter

Performance

  • $41.14
    $42.95
    $42.00
    downward going graph

    2.04%

    Downside

    Day's Volatility :4.2%

    Upside

    2.21%

    downward going graph
  • $5.65
    $65.60
    $42.00
    downward going graph

    86.55%

    Downside

    52 Weeks Volatility :91.39%

    Upside

    35.98%

    downward going graph

Returns

PeriodJanux Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
8.22%
0.4%
0.0%
6 Months
306.58%
8.7%
0.0%
1 Year
234.13%
10.3%
0.0%
3 Years
51.13%
17.0%
-23.8%

Highlights

Market Capitalization
2.2B
Book Value
$12.65
Earnings Per Share (EPS)
-1.2
Wall Street Target Price
68.57
Profit Margin
0.0%
Operating Margin TTM
-1610.3%
Return On Assets TTM
-8.74%
Return On Equity TTM
-11.5%
Revenue TTM
7.3M
Revenue Per Share TTM
0.16
Quarterly Revenue Growth YOY
-38.9%
Gross Profit TTM
-44.8M
EBITDA
-70.8M
Diluted Eps TTM
-1.2
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.31
EPS Estimate Next Year
-1.67
EPS Estimate Current Quarter
-0.33
EPS Estimate Next Quarter
-0.32

Analyst Recommendation

Buy
    93%Buy
    6%Hold
    0
    0%Sell
Based on 15 Wall street analysts offering stock ratings for Janux Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
13
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 63.26%

Current $42.00
Target $68.57

Technicals Summary

Sell

Neutral

Buy

Janux Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Janux Therapeutics Inc
Janux Therapeutics Inc
-11.6%
306.58%
234.13%
51.13%
51.13%
Moderna, Inc.
Moderna, Inc.
5.54%
63.93%
8.78%
-29.22%
787.95%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
7.08%
21.82%
32.37%
97.97%
233.31%
Novo Nordisk A/s
Novo Nordisk A/s
7.11%
43.97%
76.7%
240.79%
458.71%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
9.1%
18.8%
38.18%
156.4%
176.63%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Janux Therapeutics Inc
Janux Therapeutics Inc
NA
NA
NA
-1.31
-0.11
-0.09
NA
12.65
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.71
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.32
30.32
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.73
49.73
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.07
31.07
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Janux Therapeutics Inc
Janux Therapeutics Inc
Buy
$2.2B
51.13%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$55.7B
787.95%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$113.1B
233.31%
30.32
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$634.9B
458.71%
49.73
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$123.6B
176.63%
31.07
39.46%

Institutional Holdings

  • RA Capital Management, LLC

    17.68%
  • FMR Inc

    14.94%
  • Orbimed Advisors, LLC

    8.25%
  • Bvf Inc

    5.63%
  • Adage Capital Partners Gp LLC

    5.35%
  • HHG PLC

    3.79%

Corporate Announcements

  • Janux Therapeutics Inc Earnings

    Janux Therapeutics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

janux therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary tumor activated t cell engager (tractr) platform technology to better treat patients suffering from cancer. janux’s initial focus is on developing a novel class of t cell engagers (tces), and its lead product candidates are designed to target clinically validated drug targets. while tce therapeutics have displayed potent anti-tumor activity in hematological cancers, developing tces to treat solid tumors have faced challenges due to the limitations of prior tce technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome, (ii) on-target, healthy tissue toxicities, and (iii) poor pharmacokinetics leading to short half-life. janux is using its tractr platform technology to engineer product candidates designed to overcome these limitations. janux is developing a broad pipeline with lead programs targeting prostate-specific membr

Organization
Janux Therapeutics Inc
Employees
68
CEO
Dr. David Alan Campbell Ph.D.
Industry
Services

FAQs